Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biontech Se ADR (BNTX)

Biontech Se ADR (BNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,618,682
  • Shares Outstanding, K 240,393
  • Annual Sales, $ 2,977 M
  • Annual Income, $ -719,920 K
  • EBIT $ -1,434 M
  • EBITDA $ -1,112 M
  • 60-Month Beta 1.29
  • Price/Sales 8.47
  • Price/Cash Flow N/A
  • Price/Book 1.26

Options Overview Details

View History
  • Implied Volatility 46.84% ( +1.88%)
  • Historical Volatility 64.77%
  • IV Percentile 69%
  • IV Rank 39.84%
  • IV High 70.47% on 04/08/25
  • IV Low 31.19% on 06/25/24
  • Put/Call Vol Ratio 0.37
  • Today's Volume 844
  • Volume Avg (30-Day) 2,522
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 61,928
  • Open Int (30-Day) 57,588

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.38
  • Number of Estimates 9
  • High Estimate 3.72
  • Low Estimate -3.48
  • Prior Year -3.62
  • Growth Rate Est. (year over year) +61.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.77 +18.71%
on 05/15/25
122.90 -13.29%
on 06/03/25
+12.07 (+12.77%)
since 05/13/25
3-Month
81.20 +31.24%
on 04/07/25
122.90 -13.29%
on 06/03/25
+9.11 (+9.34%)
since 03/13/25
52-Week
76.53 +39.25%
on 08/05/24
131.49 -18.95%
on 09/17/24
+10.57 (+11.01%)
since 06/13/24

Most Recent Stories

More News
BMY Reports Positive Data on Sotyktu From Arthritis Study

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint.Sotyktu is an oral, selective tyrosine kinase...

BAYRY : 7.8700 (-1.99%)
NVS : 119.45 (-1.09%)
BMY : 49.75 (-1.85%)
BNTX : 106.57 (+1.57%)
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.6080 (+5.39%)
ARVN : 7.39 (-2.38%)
NVS : 119.45 (-1.09%)
ONC.TO : 0.82 (+6.49%)
PFE : 24.54 (-1.21%)
BNTX : 106.57 (+1.57%)
BMY : 49.75 (-1.85%)
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

ONCY : 0.6080 (+5.39%)
ARVN : 7.39 (-2.38%)
NVS : 119.45 (-1.09%)
ONC.TO : 0.82 (+6.49%)
PFE : 24.54 (-1.21%)
BNTX : 106.57 (+1.57%)
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter’s investigational bispecific antibody...

MRK : 81.71 (-0.13%)
PFE : 24.54 (-1.21%)
BMY : 49.75 (-1.85%)
BNTX : 106.57 (+1.57%)
Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

$SPX : 5,976.97 (-1.13%)
MRK : 81.71 (-0.13%)
RHHBY : 41.3200 (-1.50%)
REGN : 529.24 (+1.42%)
PFE : 24.54 (-1.21%)
BNTX : 106.57 (+1.57%)
BMY : 49.75 (-1.85%)
Bristol Myers Collaborates With BNTX for Oncology Candidate

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX.Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s...

NVS : 119.45 (-1.09%)
PFE : 24.54 (-1.21%)
BMY : 49.75 (-1.85%)
BNTX : 106.57 (+1.57%)
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double

Analysts are uber bullish on Actuate Therapeutics and PDS Biotechnology stocks for the next 12 months. Here’s why.

PDSB : 1.7500 (-2.23%)
ACTU : 8.65 (+0.46%)
BMY : 49.75 (-1.85%)
BNTX : 106.57 (+1.57%)
Why BioNTech Stock Soared Today

Bristol Myers Squibb just agreed to shower BioNTech with cash.

NFLX : 1,212.15 (-0.24%)
PFE : 24.54 (-1.21%)
BNTX : 106.57 (+1.57%)
BMY : 49.75 (-1.85%)
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

Shares of prominent COVID-19 vaccine-makers Moderna MRNA, Pfizer PFE and BioNTech BNTX rose yesterday after the FDA issued new guidance for COVID-19 vaccine boosters.FDA’s New Requirements for COVID-19...

MRNA : 26.67 (-2.49%)
PFE : 24.54 (-1.21%)
BNTX : 106.57 (+1.57%)
Why BioNTech Stock Got Trounced on Tuesday

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX) . Investors were concerned about the latest top-level...

NFLX : 1,212.15 (-0.24%)
C : 76.36 (-2.39%)
PFE : 24.54 (-1.21%)
BNTX : 106.57 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

See More

Key Turning Points

3rd Resistance Point 110.39
2nd Resistance Point 109.04
1st Resistance Point 107.81
Last Price 106.57
1st Support Level 105.23
2nd Support Level 103.88
3rd Support Level 102.64

See More

52-Week High 131.49
Fibonacci 61.8% 110.50
Last Price 106.57
Fibonacci 50% 104.01
Fibonacci 38.2% 97.52
52-Week Low 76.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar